Bisphosphonate-related osteonecrosis of the jaws – Characteristics, risk factors, clinical features, localization and impact on oncological treatment

American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65: 369–376, 2007

Abu-Id, 2008, “Bis-phossy jaws” – high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw, J Craniomaxillofac Surg, 36, 95, 10.1016/j.jcms.2007.06.008

Agis, 2010, Is zoledronate toxic to human periodontal fibroblasts?, J Dent Res, 89, 40, 10.1177/0022034509354298

Allen, 2009, The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data, J Oral Maxillofac Surg, 67, 61, 10.1016/j.joms.2009.01.007

Bamias, 2005, Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors, J Clin Oncol, 23, 8580, 10.1200/JCO.2005.02.8670

Berenson, 2002, American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma, J Clin Oncol, 20, 3719, 10.1200/JCO.2002.06.037

Berenson, 1996, Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group, N Engl J Med, 334, 488, 10.1056/NEJM199602223340802

Black, 1996, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group, Lancet, 348, 1535, 10.1016/S0140-6736(96)07088-2

Boonyapakorn, 2008, Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies, Oral Oncol, 44, 857, 10.1016/j.oraloncology.2007.11.012

Cranney, 2002, Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis, Endocr Rev, 23, 517, 10.1210/er.2001-3002

Dimopoulos, 2006, Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid, Haematologica, 91, 968

Dimopoulos, 2009, Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid, Ann Oncol, 20, 117, 10.1093/annonc/mdn554

Filleul, 2010, Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases, J Cancer Res Clin Oncol, 136, 1117, 10.1007/s00432-010-0907-7

Hansen, 2006, Osteonecrosis of the jaws in patients treated with bisphosphonates – histomorphologic analysis in comparison with infected osteoradionecrosis, J Oral Pathol Med, 35, 155, 10.1111/j.1600-0714.2006.00391.x

Hoff, 2008, Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates, J Bone Miner Res, 23, 826, 10.1359/jbmr.080205

Khosla, 2007, Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research, J Bone Miner Res, 22, 1479, 10.1359/jbmr.0707onj

Kyrgidis, 2008, Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients, J Clin Oncol, 26, 4634, 10.1200/JCO.2008.16.2768

Lesclous, 2009, Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?, Bone, 45, 843, 10.1016/j.bone.2009.07.011

Marx, 2003, Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic, J Oral Maxillofac Surg, 61, 1115, 10.1016/S0278-2391(03)00720-1

Mawardi, 2009, Sinus tracts – an early sign of bisphosphonate-associated osteonecrosis of the jaws?, J Oral Maxillofac Surg, 67, 593, 10.1016/j.joms.2008.09.031

Migliorati, 2003, Bisphosphonates and oral cavity avascular bone necrosis, J Clin Oncol, 21, 4253, 10.1200/JCO.2003.99.132

Oizumi, 2010, Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs, J Oral Maxillofac Surg, 68, 1043, 10.1016/j.joms.2009.08.027

Orriss, 2009, Inhibition of osteoblast function in vitro by aminobisphosphonates, J Cell Biochem, 106, 109, 10.1002/jcb.21983

Otto, 2009, The role of inferior alveolar nerve involvement in bisphosphonate-related osteonecrosis of the jaw, J Oral Maxillofac Surg, 67, 589, 10.1016/j.joms.2008.09.028

Otto, 2010, Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle?, J Oral Maxillofac Surg, 68, 1158, 10.1016/j.joms.2009.07.079

Otto, 2010, Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism, J Oral Maxillofac Surg, 68, 2837, 10.1016/j.joms.2010.07.017

Otto, 2011, Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: not just a sporadic coincidence – a multi-centre study, J Craniomaxillofac Surg, 39, 272, 10.1016/j.jcms.2010.05.009

Reid, 2007, Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?, Bone, 41, 318, 10.1016/j.bone.2007.04.196

Ripamonti, 2009, Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan, Ann Oncol, 20, 137, 10.1093/annonc/mdn526

Roelofs, 2009, Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP, Br J Haematol, 144, 245, 10.1111/j.1365-2141.2008.07435.x

Ruggiero, 2009, American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws – 2009 update, J Oral Maxillofac Surg, 67, 2, 10.1016/j.joms.2009.01.009

Ruggiero, 2004, Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases, J Oral Maxillofac Surg, 62, 527, 10.1016/j.joms.2004.02.004

Sato, 1991, Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure, J Clin Invest, 88, 2095, 10.1172/JCI115539

Scavelli, 2007, Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma, Mol Cancer Ther, 6, 3256, 10.1158/1535-7163.MCT-07-0311

Sedghizadeh, 2008, Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy, J Oral Maxillofac Surg, 66, 767, 10.1016/j.joms.2007.11.035

Walter, 2009, Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients, Cancer, 115, 1631, 10.1002/cncr.24119

Wang, 2003, Osteonecrosis of the jaws associated with cancer chemotherapy, J Oral Maxillofac Surg, 61, 1104, 10.1016/S0278-2391(03)00328-8